Understanding the microbiome of diabetic foot osteomyelitis: insights from molecular and microscopic approaches.


Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420

Informations de publication

Date de publication:
Mar 2019
Historique:
received: 06 03 2018
revised: 30 04 2018
accepted: 30 04 2018
pubmed: 23 5 2018
medline: 20 9 2019
entrez: 23 5 2018
Statut: ppublish

Résumé

Rigorous visual evidence on whether or not biofilms are involved in diabetic foot osteomyelitis (DFO) is lacking. We employed a suite of molecular and microscopic approaches to investigate the microbiome, and phenotypic state of microorganisms involved in DFO. In 20 consecutive subjects with suspected DFO, we collected intraoperative bone specimens. To explore the microbial diversity present in infected bone we performed next generation DNA sequencing. We used scanning electron microscopy (SEM) and peptide nucleic acid fluorescent in situ hybridization (PNA-FISH) with confocal microscopy to visualize and confirm the presence of biofilms. In 19 of 20 (95%) studied patients presenting with DFO, it was associated with an infected diabetic foot ulcer. By DNA sequencing of infected bone, Corynebacterium sp. was the most commonly identified microorganism, followed by Finegoldia sp., Staphylococcus sp., Streptococcus sp., Porphyromonas sp., and Anaerococcus sp. Six of 20 bone samples (30%) contained only one or two pathogens, while the remaining 14 (70%) had polymicrobial communities. Using a combination of SEM and PNA-FISH, we identified microbial aggregates in biofilms in 16 (80%) bone specimens and found that they were typically coccoid or rod-shaped aggregates. The presence of biofilms in DFO may explain why non-surgical treatment of DFO, relying on systemic antibiotic therapy, may not resolve some chronic infections caused by biofilm-producing strains.

Identifiants

pubmed: 29787888
pii: S1198-743X(18)30421-X
doi: 10.1016/j.cmi.2018.04.036
pii:
doi:

Substances chimiques

DNA, Bacterial 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

332-339

Informations de copyright

Copyright © 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Auteurs

K Johani (K)

Surgical Infection Research Group, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia.

B G Fritz (BG)

University of Copenhagen, Faculty of Health and Medical Sciences, Department of Immunology and Microbiology, Costerton Biofilm Center, Denmark.

T Bjarnsholt (T)

University of Copenhagen, Faculty of Health and Medical Sciences, Department of Immunology and Microbiology, Costerton Biofilm Center, Denmark; Department of Clinical Microbiology, Rigshospitalet, Denmark.

B A Lipsky (BA)

Oxford Microbiology and Infectious Diseases, University of Oxford, Oxford, UK.

S O Jensen (SO)

Infectious Diseases and Microbiology, School of Medicine, Western Sydney University, Australia.

M Yang (M)

Liverpool Hospital, South Western Sydney LHD, Sydney, Australia.

A Dean (A)

Liverpool Hospital, South Western Sydney LHD, Sydney, Australia.

H Hu (H)

Surgical Infection Research Group, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia.

K Vickery (K)

Surgical Infection Research Group, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia.

M Malone (M)

Infectious Diseases and Microbiology, School of Medicine, Western Sydney University, Australia; Liverpool Hospital, South Western Sydney LHD, Sydney, Australia; Liverpool Diabetes Collaborative Research Unit, Ingham Institute of Applied Medical Research, Sydney, Australia. Electronic address: matthew.malone@health.nsw.gov.au.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH